Skip to main content

Table 4 Hazard ratios for overall survival 1, 2 and 5 years after start of [ 90 Y-DOTA]-TOC Therapy ( n = 359 )

From: Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study

  

1-YEAR SURVIVAL

2-YEARS SURVIVAL

5-YEARS SURVIVAL

Covariate

 

Hazard ratio (95% CI)*

P Value

Hazard ratio (95% CI)*

P Value

Hazard ratio (95% CI)*

P Value

Gender

(male vs. females)

1.00 (0.61-1.63)

0.99

1.08 (0.75-1.57)

0.66

1.00 (0.75-1.35)

0.98

Age

(per 10 years)

1.00 (0.98-1.02)

0.69

0.99 (0.98-1.00)

0.19

1.00 (0.99-1.01)

0.83

Duration of Disease

(per year)

0.94 (0.86-1.04)

0.22

0.93 (0.86-0.99)

0.03

0.97 (0.93-1.01)

0.16

Previous Surgery

(vs. no surgery)

0.59 (0.33-1.04)

0.07

0.57 (0.38-0.87)

0.009

0.63 (0.45-0.87)

0.006

Previous Chemotherapy

(vs. no chemotherapy)

1.28 (0.75-2.19)

0.37

1.28 (0.86-1.93)

0.23

1.68 (1.21-2.32)

0.002

Previous Radiation

(vs. no radiation)

0.63 (0.31-1.31)

0.22

0.75 (0.45-1.25)

0.27

0.93 (0.62-1.39)

0.72

Solitary Metastases

(vs. multiple metastases)

0.38 (0.11-1.37)

0.14

0.60 (0.22-1.60)

0.31

0.63 (0.29-1.38)

0.25

Liver Metastases

(vs. no liver metastases)

1.83 (0.68-4.95)

0.24

1.40 (0.68-2.92)

0.36

1.57 (0.88-2.80)

0.13

Bone Metastases

(v. no bone metastases)

1.59 (0.90-2.81)

0.11

1.18 (0.74-1.87)

0.49

1.38 (0.94-2.01)

0.10

Tumor Uptake Score 2

(vs. uptake score 1)

1.47 (0.35-6.14)

0.60

2.10 (0.69-6.42)

0.19

0.77 (0.31-1.92)

0.58

Tumor Uptake Score 3

(vs. uptake score 1)

0.51 (0.13-2.09)

0.35

0.85 (0.28-2.61)

0.78

0.40 (0.16-0.98)

0.05

Low Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.93 (0.19-4.58)

0.93

0.39 (0.13-1.19)

0.10

0.39 (0.16-0.96)

0.04

Intermediate Dose [90Y-DOTA]-TOC

(vs. High Dose)

0.74 (0.24-2.31)

0.61

0.52 (0.25-1.11)

0.09

0.57 (0.33-0.99)

0.05

  1. *Estimates for each co-variable have been adjusted for histology as a categorical co-variable, for the cumulative [90Y-DOTA]-TOC activity as well as for all other co-variables listed.